We are grateful for the support of our Sponsors Genentech, The National Institutes of Health and JDRF. As always, Nature carries sole responsibility for all editorial content.


Corporate Sponsor: Genentech

GenetechFor nearly 30 years, the name Genentech has been synonymous with high-quality, innovative science. The company's emphasis on strong, visionary research combined with an applied, creative focus on unmet medical needs has been instrumental to transforming care for certain patients.

Discovery research at Genentech focuses primarily on three areas of medicine: oncology, immunological disease, and disorders of tissue growth and repair, with a major focus on angiogenic disorders. Genentech scientists are at the forefront of angiogenesis research in their efforts to develop a new generation of cancer therapies, as well as a therapeutic antibody currently being studied in wet age-related macular degeneration, the leading form of age-related blindness in the world. Ongoing study into angiogenesis suggests potential therapeutic implications not only for cancer and blindness, but possibly for heart disease and wound-healing as well.

Genentech's scientists and medical professionals strive to translate basic science into patient benefit. Our experience in developing multiple protein-based products into therapeutics for serious or life-threatening medical conditions, along with our diversity and dedication to research may position Genentech to continue playing a significant role in discovering new treatments.

At Genentech, we are in business for life.

For more information on Genentech's research in these areas, please visit


Academic Sponsors: The National Institutes of Health (NIH) and JDRF

NIHJDRFThe National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services, comprises 27 Institutes and Centers conducting biomedical research directed toward improving human health worldwide. The Juvenile Diabetes Research Foundation (JDRF) is a non-profit foundation dedicated to finding a cure for Type 1 Diabetes and its complications through the support of research.

The Trans-Institute Angiogenesis Research Program (TARP) was created to foster coordination of angiogenesis research programs across NIH and with JDRF. The members of TARP, the National Cancer Institute (NCI), National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), National Heart, Lung and Blood Institute (NHLBI), National Institute of Neurological Diseases and Stroke (NINDS), National Eye Institute (NEI) and JDRF, are committed to a broad perspective on the field of angiogenesis. Each of the member institutes has a vision that this coordination of efforts through TARP will accelerate research discoveries in angiogenesis for the prevention, treatment and cure of diseases within their missions.